Barclays’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-9,100
| Closed | -$6.48M | – | 5506 |
|
|
2024
Q4 | $6.48M | Buy |
9,100
+200
| +2% | +$168K | ﹤0.01% | 1926 |
|
|
2024
Q3 | $9.36M | Buy |
+8,900
| New | +$9.9M | ﹤0.01% | 1528 |
|
|
2022
Q3 | – | Sell |
-7,000
| Closed | -$4.14M | – | 5074 |
|
|
2022
Q2 | $4.14M | Buy |
+7,000
| New | +$4.55M | ﹤0.01% | 1439 |
|
|
2021
Q2 | – | Sell |
-15,000
| Closed | -$7.1M | – | 5047 |
|
|
2021
Q1 | $7.1M | Buy |
+15,000
| New | +$7.3M | ﹤0.01% | 1251 |
|
|
2020
Q4 | – | Sell |
-1,900
| Closed | -$1.06M | – | 5119 |
|
|
2020
Q3 | $1.06M | Buy |
+1,900
| New | +$1.15M | ﹤0.01% | 2632 |
|
|
2020
Q2 | – | Sell |
-24,800
| Closed | -$12.1M | – | 6128 |
|
|
2020
Q1 | $12.1M | Sell |
24,800
-24,400
| -50% | -$10.1M | 0.01% | 885 |
|
|
2019
Q4 | $18.5M | Sell |
49,200
-30,000
| -38% | -$10.1M | 0.01% | 993 |
|
|
2019
Q3 | $22M | Sell |
79,200
-4,900
| -6% | -$1.45M | 0.01% | 826 |
|
|
2019
Q2 | $26.3M | Buy |
84,100
+54,500
| +184% | +$18.1M | 0.02% | 782 |
|
|
2019
Q1 | $12.2M | Sell |
29,600
-10,400
| -26% | -$4.28M | 0.01% | 1110 |
|
|
2018
Q4 | $14.9M | Buy |
40,000
+9,100
| +29% | +$3.33M | 0.01% | 921 |
|
|
2018
Q3 | $12.5M | Sell |
30,900
-34,600
| -53% | -$13.2M | 0.01% | 1138 |
|
|
2018
Q2 | $22.6M | Buy |
65,500
+20,500
| +46% | +$6.41M | 0.02% | 731 |
|
|
2018
Q1 | $15.5M | Sell |
45,000
-70,800
| -61% | -$24.6M | 0.01% | 976 |
|
|
2017
Q4 | $43.5M | Buy |
115,800
+39,100
| +51% | +$15.8M | 0.04% | 470 |
|
|
2017
Q3 | $34.3M | Sell |
76,700
-135,700
| -64% | -$64.6M | 0.04% | 445 |
|
|
2017
Q2 | $104M | Buy |
212,400
+159,400
| +301% | +$69.8M | 0.11% | 135 |
|
|
2017
Q1 | $20.5M | Buy |
53,000
+16,200
| +44% | +$6M | 0.02% | 547 |
|
|
2016
Q4 | $13.5M | Buy |
36,800
+5,400
| +17% | +$2.05M | 0.01% | 798 |
|
|
2016
Q3 | $12.6M | Sell |
31,400
-5,800
| -16% | -$2.33M | 0.01% | 744 |
|
|
2016
Q2 | $13M | Buy |
37,200
+16,500
| +80% | +$6.35M | 0.02% | 709 |
|
|
2016
Q1 | $7.45M | Sell |
20,700
-13,500
| -39% | -$5.56M | 0.01% | 925 |
|
|
2015
Q4 | $18.5M | Sell |
34,200
-18,600
| -35% | -$10.1M | 0.02% | 605 |
|
|
2015
Q3 | $24.6M | Sell |
52,800
-36,600
| -41% | -$19.7M | 0.03% | 504 |
|
|
2015
Q2 | $45.6M | Buy |
89,400
+33,700
| +61% | +$16.4M | 0.05% | 316 |
|
|
2015
Q1 | $25.1M | Sell |
55,700
-37,700
| -40% | -$16M | 0.03% | 577 |
|
|
2014
Q4 | $38.3M | Buy |
93,400
+36,100
| +63% | +$14.2M | 0.04% | 451 |
|
|
2014
Q3 | $20.6M | Buy |
57,300
+34,600
| +152% | +$11.6M | 0.02% | 698 |
|
|
2014
Q2 | $6.4M | Sell |
22,700
-8,200
| -27% | -$2.43M | 0.01% | 1520 |
|
|
2014
Q1 | $9.27M | Sell |
30,900
-30,200
| -49% | -$9.3M | 0.01% | 1202 |
|
|
2013
Q4 | $16.8M | Sell |
61,100
-13,300
| -18% | -$3.83M | 0.02% | 870 |
|
|
2013
Q3 | $23.2M | Buy |
74,400
+34,900
| +88% | +$9.18M | 0.03% | 593 |
|
|
2013
Q2 | $8.88M | Buy |
+39,500
| New | +$9.2M | 0.01% | 1164 |
|
Other funds holding REGN
VCM
N
Barclays's REGN Position: Q1 2026 in Review
Barclays increased its Regeneron Pharmaceuticals (REGN) stake by 0.62% in Q1 2026, buying an estimated $1.47M and bringing the position to 313,093 shares worth $242M. The position accounts for 0.06% of the portfolio, ranked #247.
Barclays first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $434M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Barclays held 313,093 shares of Regeneron Pharmaceuticals worth $242M as of Q1 2026.
- Barclays bought 1,926 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.47M.
- Regeneron Pharmaceuticals made up 0.06% of Barclays's portfolio in Q1 2026, its #247 holding.
- Barclays first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Barclays's Regeneron Pharmaceuticals position peaked at $434M in Q3 2024.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.